The Tisch Cancer Institute

  1. Research
doctor smiling at patient

Cancer Clinical Investigation

Cancer Clinical Investigation

The goal of the Cancer Clinical Investigation (CCI) Program is to leverage the TCI’s pioneering science to maximally impact cancer treatment through the preclinical and clinical development of cutting-edge treatment strategies. CCI members, through their complementary and synergistic expertise, work to identify novel therapeutic strategies and advance TCI discoveries from the laboratory to the clinic and back, leading to constant cycles of scientific innovation. In addition to translating research that is initiated from within the Program, the CCI program is responsible for translating the science that emerges from other programs into novel therapeutic approaches and clinical trials for cancer patients by collaborating with other TCI Programs.

Program Goals

  • To develop therapies, and associated biomarkers, relevant to cancer cell-intrinsic processes
  • To develop therapies, and associated biomarkers, relevant to the host immune system and the tumor microenvironment
Find A Clinical Trial Make a Gift Discover Careers

Cancer Clinical Investigation Research Program Leaders

Matthew Galsky, MD
Matthew Galsky, MD

Associate Director, Translational Research

Jian Jin, PhD
Jian Jin, PhD

Professor, Therapeutics Discovery, Oncological Sciences, Pharmacological Sciences, Neuroscience
Director, Mount Sinai Center for Therapeutics Discovery

Samir Parekh, MBBS
Samir Parekh, MBBS

Professor, Medicine (Hematology and Medical Oncology), and Oncological Sciences, and Immunology and Immunotherapy
Director, Translational Research in Multiple Myeloma

Members

AT A GLANCE

Cancer Clinical Investigation Research

4195
Publications
3769
Press/Media

45 Researchers

Researchers Image 1
Researchers Image 2
Researchers Image 5
Researchers Image 6
View All Researchers

Recent Publications

An update on dermatological trends among emergency department visits a cross-sectional analysis, 2017–2021. Archives of Dermatological Research

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. npj Precision Oncology

Dermatology access for patients with neurofibromatosis type 1 (NF1) a survey study. Archives of Dermatological Research

View Full Details

Moving the Field Forward

Find out how we collaborate to address cancer’s most complex challenges.

Stuart A. Aaronson, MD: 2024 Jacobi Medallion Recipient
Thomas Marron, MD, PhD – AACR Annual Meeting 2023
Ramon Parsons, MD, PhD: 2023 Jacobi Medallion Recipient
2022 Distinguished Scholar Award - Dr. Alice Kamphorst
Center of Excellence: Liver and Bile Duct Cancer
Tisch Cancer Institute COVID-19 Research Briefing: May 14, 2020
Watch Videos

Resources For You

Cancer Centers of Excellence
Patient Care
Oncological Sciences
Division of Hematology and Medical Oncology
Residencies and Fellowships
Shared Resources
TCI Newsletter

Contact Us

The Tisch Cancer Institute

One Gustave L. Levy Place

Box 1128

New York, NY 10029-6574

Christine Ponder, PhD, MPA
Director, Research Administration

Email

Patient Information
The Clinical Research Support Unit

212-824-7391
Email